Topics of the NCT Trial Center´s newsletter in December 2018 are:
- PMO-1603 TOP-ART, a phase II study of locally advanced or metastatic solid neoplasia regardless of histological entity, launched in several German centers
- N2M2, a successfully launched umbrella study, in which glioblastoma patients are included in one of five sub studies depending on specific molecular markers or – in the absence of these markers – are randomized into one of three other sub studies
- PERDAM, a recently launched meta-study evaluating measurable residual disease as surrogate parameter for therapy response in AML
- TEAM, a study using an innovative Matched Threshold Crossing approach to sample size calculation
- News from the field of laws and regulations
Download (PDF-File): Newsletter December 2018 | German»
Download (PDF-File): Newsletter December 2018 | English »